Business Context and Reporting Period
This Form 6-K filing by Evogene Ltd. covers the month of February 2025. The report details the status of the Company's Special General Meeting of Shareholders (Annual Meeting) originally convened on February 5, 2025.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This document is a procedural notice regarding a shareholder meeting and does not contain financial statements or performance data.
Material Changes
No material financial changes versus the prior comparable period are reported in this filing. The only material event noted is the procedural adjournment of the Annual Meeting due to a lack of quorum.
Guidance, Outlook, and Management Commentary
- Meeting Adjournment: The Special General Meeting held on February 5, 2025, was adjourned for one week due to a lack of quorum.
- Reconvened Meeting: The meeting is scheduled to be reconvened on Wednesday, February 12, 2025, at 3:00 p.m. (Israel time).
- Location: The reconvened meeting will take place at the Company's executive offices at 13 Gad Feinstein Street, Park Rehovot, Rehovot, Israel.
- Regulatory Status: The content of this report is incorporated by reference into the Company's registration statements on Form F-3 and Form S-8.
Key Facts for Investor Verification
- Verify the outcome of the reconvened Special General Meeting scheduled for February 12, 2025.
- Confirm whether the lack of quorum on February 5, 2025, impacts any pending shareholder proposals or corporate actions.
- Review subsequent filings for the actual financial results and operational updates that were likely the subject of the Annual Meeting.